Professor Louise Bowman
- AMALFI - Active Monitoring for Atrial Fibrillation
- ASCEND: A Study of Cardiovascular Events iN Diabetes
- HPS3 / TIMI 55 - REVEAL : Randomised EValuation of the Effects of Anacetrapib through Lipid-modification
- Research Regulation
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- Trials Methodology
BA, MBBS, MD, FRCP
Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)
- Clinical Trial Service Unit
- MRC PHRU Programme Leader
Louise Bowman is Professor of Medicine and Clinical Trials at the Clinical Trial Service Unit of the University of Oxford. Her specialist clinical background is in Diabetes and Endocrinology. She has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics. She is Chief Investigator for the ORION-4 trial which will assess the effects of inclisiran on clinical outcomes among 15,000 people with atherosclerotic cardiovascular disease, and for the AMALFI trial, which will assess the value of screening for undiagnosed atrial fibrillation in high-risk individuals.
Prof Bowman is also Co-principal Investigator for the recently-reported ASCEND trial, which studied the effects of aspirin and of omega-3 fatty acid supplementation for the primary prevention of cardiovascular disease in 15,000 people with diabetes, and for the REVEAL study, an international clinical trial that assessed the efficacy and safety of the CETP-inhibitor, anacetrapib, in 30,000 high-risk individuals.
Through her work on large-scale trials in cardiovascular disease she has developed a specialist interest in Clinical Trials Methodology and is Director of the Oxford CTSU Hub for the MRC Network of Hubs for Trials Methodology Research (HTMR). Her focus is on the development, application and widespread promotion of methods to enhance the design and conduct of trials to ensure high quality outputs and reliable results at low cost.
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.
Hopewell JC. et al, (2020), Eur Heart J, 41, 3336 - 3342
Randomization versus Real-World Evidence. Reply.
Collins R. et al, (2020), N Engl J Med, 383
The Magic of Randomization versus the Myth of Real-World Evidence.
Collins R. et al, (2020), N Engl J Med, 382, 674 - 678
Understanding the use of observational and randomized data in cardiovascular medicine.
Bowman L. et al, (2020), Eur Heart J
Effects of Omega-3 Fatty Acid Supplements on Arrhythmias.
Parish S. et al, (2020), Circulation, 141, 331 - 333